Sign In
Get Clay Free →

Suggestions

    Mewa Singh

    Chief Executive Officer at Meda Biotech Inc. Affordable treatment of cancer for all

    Mewa Singh is a seasoned professional specializing in process and product development within the biopharmaceutical industry, with a primary focus on vaccines, enzymes, antibodies, and viruses.

    With a strong background in biopharmaceuticals, Mewa has successfully overseen the development and delivery of over 25 products, ranging from vaccines to therapeutics and diagnostics.

    Her expertise extends to ADC designing, process development, and production of various biopharmaceuticals, including Fab, ScFv, minibodies, and full antibodies.

    Mewa has also been involved in developing conjugated recombinant antibodies with drugs for the treatment of cancer and infectious diseases, with several molecules currently undergoing trials for drug development.

    In addition to her technical skills, Mewa excels in project management, leadership, and setting up new laboratories and manufacturing plants in the biopharmaceutical sector.

    She is known for her problem-solving abilities, team-building skills, and hands-on experience in upstream process development and immunoassay development.

    Mewa has led cross-functional teams working on various projects related to vaccines, antibodies, antibody-drug conjugates (ADCs) for cancer, and infectious diseases.

    Currently, Mewa is focusing on a new project aimed at resolving the solubility issues of 85 drugs using patented technology called Hybrid-Nanoengineering™.

    Some of the pipeline drugs Mewa is working on include Paclitaxel, Docetaxel, Cisplatin, Celebrex, and the next generation of Herceptin.

    She is actively involved in multiple project plans, such as MewDoxel and MewTaxel, which are new nanomedicine formulations for Docetaxel and Paclitaxel, respectively, seeking funds for clinical trials.

    Another project plan involves developing a new formulation for colorectal cancer, also in need of financial support for clinical trials.

    Mewa holds patents for hybrid drugs for cancer using Hybrid-Nanoengineering™, an oral vaccine, and a new compound for acid reflux (GERD).

    She pursued her Master of Philosophy (MPhil) and PhD in Biology/Biological Sciences at Guru Nanak Dev University.

    Currently, Mewa Singh is the Chief Executive Officer at Meda Biotech Inc., in collaboration with www.taxolcur.com, having previously held roles as COO at Meda Biotech llc., COO at Meda Biotech, Director (Process and Technology) at Tempest Biotech, and CSO at J N international and RMZ biotech.

    Mewa Singh
    Add to my network

    Location

    Baton Rouge, Louisiana, United States
    Location